Skin Cancer

Latest News


In a recent phase 2 study, nearly half of patients who had resectable stage 3B/C BRAF V600-mutant melanoma achieved pathologic complete response (pCR) – meaning that no active cancer cells are present – with neoadjuvant combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib).

An injured cancer survivor reluctantly but gratefully copes with neuropathy, osteopenia and stiff-joint cancer side effects after recently breaking her foot and getting surgery.

A new drug may be on the way to treat patients with advanced melanoma, as the FDA granted LN-144, which is produced by Iovance Biotherapeutics, a fast track designation. The drug uses tumor-infiltrating lymphocyte (TIL) technology to bolster the body’s immune system to attack cancer cells.

Yervoy (ipilimumab) was granted approval by the Food and Drug Administration (FDA) for the treatment of pediatric patients who are 12 years old or younger and have unresectable or metastatic melanoma, according to Bristol-Myers Squibb (BMS), the manufacturer of the CTLA-4 inhibitor.